Hycult Biotech News
Plasma biomarkers of pulmonary and extra-pulmonary tuberculosis in children
Kumar, NP et al. Circulating biomarkers of pulmonary and extra-pulmonary tuberculosis in children. Clin. Vaccine Immunol. 2013, 13 March.
The global impact of childhood tuberculosis is unknown because of lack of reports. Under adults there is an estimated 9 million new infections and 1.7 million deaths per year. It is generally reported that at least 10-15% of cases in the world occur in children.
The golden standard for diagnosing TB is microbiological culture, however this often fails in children. Recent studies also show that tests based on nucleic acid amplification fail with the same reasons. Immuno assays based on plasma samples can possibly improve the diagnosis.
In this study, many biomarkers of the pathogenesis of TB have been examined. Also a few markers of the innate immunity have been examined, including LPS, LBP, sCD14 and antibodies to the LPS core (EndoCab). In previous papers, these markers have proven their role in various infectious diseases like HIV, hepatitis and parasitic infections.
The current findings reveal that LPS, LBP and EndoCab levels can serve as discriminating markers between pulmonary and extra-pulmonary disease in children. Suppressed levels of LPS and LBP and increased levels of EndoCab are present in extra-pulmonary disease compared to pulmonary disease. Interestingly, the levels between healthy control children and children with pulmonary disease were not significant different. This means that persistant immune activation is not need fully a hallmark of pulmonary TB in children.
In conclusion, this study reports the potential of certain factors in diagnosing pulmonary and extra-pulmonary disease in children. More studies are needed to provide more insight in pediatric tuberculosis.
|LAL Chromogenic Endpoint Assay||3 x 96 det.||HIT302|
|EndoCab IgM, Human, ELISA||1 x 96 det.||HK504-IgM|
|EndoCab IgG, Human, ELISA||1 x 96 det.||HK504-IgG|
|EndoCab IgA, Human, ELISA||1 x 96 det.||HK504-IgA|
|EndoCab, Human, ELISA kit||1 x 96 det.||HK504|
|LBP, Human, ELISA kit||1 x 96 det.||HK315-01|
|TNF-alpha, Human, ELISA kit||1 x 96 det.||HK307-01|
|IFN-gamma, Human, ELISA kit (medium & serum)||1 x 96 det.||HK309-01|
|SAA, Human, ELISA kit||1 x 96 det.||HK333-01|
|CRP, Human, ELISA kit||1 x 96 det.||HK358|
|sCD14, Human, ELISA kit||1 x 96 det.||HK320-01|
Lipopolysaccharide-binding protein: a potential marker of febrile urinary tract infection in childhood
Thursday, May 2, 2013
Tsalkidou, E.A et al. Pediatr. Nephrol. 2013 March 6.
Children frequently suffer from urinary tract infections. Current clinical practice is evaluation of conventional serum markers like total white blood cell count, erythrocyte sedimentation rate, C-reactive protein (CRP), procalcitonin (PCT) and Interleukin-6 (IL-6).
Accurate diagnosis and early treatment of urinary tract infections are of pivotal importance in particularly for infancy and early childhood. A candidate marker is LBP, an acute phase protein produced by the liver. LBP has high affinity to lipopolysaccharide (LPS) and in transferring monomeric LPS to CD14. CD14 accelerate LPS recognition by Toll Like Receptor 4 (TLR-4) which induces the release of cascade of pro-inflammatory cytokines. These cytokines are the key mediators in the pathogenesis of the systemic inflammatory response.
LBP is present in plasma of healthy individuals at concentrations of 2 – 10 mg/l and rapidly increases in case of infections. This study reports that inflammation–free children at the age of 10 years have a mean concentration of 27.66 mg/l and a range of 11.82 -43.50 mg/l. Children with urinary tract infections have a mean concentration of 95.55mg/l and range of 36.75 – 241.25 mg/l.
The results show a sensitivity, negative predictive value, specificity and positive predictive value superior for LBP. These findings suggest that LBP is a better diagnostic marker for urinary tract infections then currently used diagnostic markers.
|LBP, Human, ELISA kit||2 x 96 det.||Cat.# HK315-02|
|LBP, Human, ELISA kit||1 x 96 det.||Cat.# HK315-01|
|LBP, Mouse, ELISA kit||1 x 96 det.||Cat.# HK205-01|
|LBP, Mouse, ELISA kit||2 x 96 det.||Cat.# HK205-02|
|sCD14, Human, ELISA kit||1 x 96 det.||Cat.# HK320-01|
|sCD14, Human, ELISA kit||2 x 96 det.||Cat.# HK320-02|
|LBP, various species, ELISA kit||1 x 96 det.||Cat.# HK503|
|EndoClear, red, small (EndoTrap red 1/1 + mini LAL)||Cat.# HIT306|
|EndoClear, blue, small (EndoTrap blue 1/1 + mini LAL)||Cat.# HIT305|
|IL-FABP, Human, pAb 100 µg||IA W||Cat.#HP9031|
|A-FABP, Human, pAb 100 µg||IA W||Cat.# HP9028|
|LBP, Human, pAb 100 µg||IA IP W||Cat.#HP9023|
|IL-FABP, Mouse, pAb 100 µg||IA P W||Cat.#HP8011|
|Lipopolysaccharide Core, mAb WN1 222-5 100 µg||FS IA P W||Cat.#HM6011|
|Lipopolysaccharide (LPS) from E.coli, Serotype O8:K27 1 mg||FS||Cat.# HC4065|
|TLR4 agonist Set: Lipopolysaccharide (LPS) from E.coli||FS||Cat.# HC4064|
Hycult Biotech now introduces the Antibody Sampler Packs. These Antibody Sampler Packs enable researchers to screen a 10 µg aliquot of multiple antibodies to determine which is best in their application. Select any 5 or 10 antibodies from the Hycult Biotech product range to design an Antibody Sample Pack specific for your research needs.
|HM8002||Human Complement Lectin Pathway; Antibody Sampler Pack|
|HM2061||MBL, Human, mAb 3E7||10 µg|
|HM2191||MASP-2/MAp19, Human, mAb 6G12||10 µg|
|HM2216||MASP-3, Human, mAb 38:12-3||10 µg|
|HM2089||H-ficolin, Human, mAb 4H5||10 µg|
|HM2091||L-ficolin, Human, mAb GN5||10 µg|
|HM2196||M-ficolin, Human, mAb 7G1||10 µg|
|HM2092||MASP-1/3, Human, mAb 1E2||10 µg|
|HM2076||C5/C5a, Human, mAb 561||10 µg|
|HM2264||C9 neoantigen, Human, mAb WU 13-15||10 µg|
|HM2167||TCC, Human, mAb aE11||10 µg|
For pricing, ordering and design, please contact email@example.com
Cat # HK215
Mouse SAP has shown to be a reliable marker of the acute phase. In mouse, SAP levels increase significantly 24 hours after challenge with lipopolysaccharide. In man, SAP does not become elevated during inflammation, whereas CRP is the prototypical acute phase reactant. CRP in mice has been isolated, but it has not been well documented as it occurs only at concentrations of nanograms per milliliter.....
Cat # HK334
The protein is produced by a variety of leukocytes, including monocytes, T lymphocytes and neutrophils , but also by endothelial cells in which properdin synthesis and release are induced by shear stress...
New New New !!! Hycult Biotech now offers 1-plate assays from a selection of 15 assays.
Catalog nr: HM1073
Short description: The monoclonal antibody BB5.1 binds the fifth component of mouse complement (C5). The complement system is a group of plasma and cell membrane proteins that play a key role in the immune system. All three pathways (classical, alternative & lectin) lead to the cleavage of C3 and eventually the formation of the cytolytic membrane attack complex C5b-9. If the activation cascade is allowed to proceed beyond ...
Size: 100 µg
Application: F , FS , IA , IP , P
Cat. nr: HC1050-01
Concentration of at least 50000 units.
Lyophilized in sodium phosphate buffer, pH 7.0, 100 µg/ml mouse albumin and 0.01%/ml gelatin .
Three types of interferons have been described: interferon-alpha (IFN-alpha), interferon-beta (IFN-beta), and interferon-gamma (IFN-gamma). An extensive variety of biological effects have been observed for the interferon family including antiviral activity; anti-proliferative activity; stimulation of cytotoxic activities in lymphocytes, natural killer cells, and macrophages; and modulation of the major histocompatibility complex.
Only one mouse-IFN-beta gene has yet been described. It codes for a 161 amino acid polypeptide (20 kD).
Mouse-IFN-beta binds to the type I interferon receptor. It is not recognized by antibodies directed against mouse alpha interferon or mouse gamma interferon.
One unit of mouse beta interferon is the amount of beta interferon which protects 50% of the indicator cell population from viral destruction. One unit of Hycult Biotech Mouse Beta Interferon approximates the bioactivity contained in one unit of the mouse beta interferon standard prepared by NIH (Gb02-902-511).